Roche Holding AG is adding an experimental drug for a blinding eye condition in a deal aimed at helping the company move further into cell-based therapies.
Roche’s Genentech drugs business said Monday that it has bought the rights to the eye drug from Lineage Cell Therapeutics Inc. for $50 million cash upfront and additional payments in the future if development, regulatory and sales milestones are met.
